Tempus AI and Daiichi Sankyo Partner for Cancer Discovery

Tempus AI and Daiichi Sankyo announced a strategic collaboration on March 25, 2026 ^[1]. The partnership focuses on using multimodal AI foundation models to accelerate biomarker discovery ^[1][2]. Specifically, the companies aim to optimize patient selection for antibody-drug conjugate (ADC) clinical programs ^[1][3]. The PRISM2 model will play a central role in this oncology research initiative ^[1]. By analyzing complex datasets, the AI tools help identify which patients are most likely to respond to specific cancer treatments ^[2]. This technical integration aims to advance clinical differentiation across Daiichi Sankyo's development portfolio ^[3].